Denali Therapeutics is dedicated to defeating neurodegenerative diseases by breaking through historical barriers in scientific research and clinical development in order to deliver safe and effective medicines to patients and families. Our scientific approach is based on three core principles: rigorous assessment of genetic targets, engineering brain delivery, and using biomarkers to guide development.
Our team thrives in a work environment that is scientifically driven, impact-focused, supportive, and collaborative. Our ability to have a positive impact on people’s lives is directly related to the trust we have in each other and our ability to unify our diverse backgrounds and experience behind our purpose to defeat degeneration.
|
|
|
201-500 employees
View all Denali Therapeutics employees
|
|
Biotechnology
|
|
161 Oyster Point Blvd, South San Francisco, California 94080, US
|
|
2015
|
|
Biotechnology, Pharmaceuticals, Neurodegeneration, Neurodegenerative Disease
|
Ryan Watts is the CEO of Denali Therapeutics. To contact Ryan Watts email at [email protected] or [email protected].
The decision makers in Denali Therapeutics are Anthony Delucchi, Cynthia Wong, Don Zhong, etc. Click to Find Denali Therapeutics decision makers emails.
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.